ARCHIVES

Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

HCFA Abadons Plan To Cut Cancer Drug Payments.

September 15, 2000

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

November 20, 1992

CPT-11, Gemcitabine Increase Survival Of Pancreatic Cancer

March 29, 2002

NCI-Approved Clinical Trials

August 25, 2006

FDA Publishes Parallel Track Rules, Accelerated Drug Approval Initiative

April 25, 1992